



WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C12N 15/12, C12Q 1/68</p>	<p>A1</p>	<p>(11) International Publication Number: WO 96/30513</p> <p>(43) International Publication Date: 3 October 1996 (03.10.96)</p>																																																																								
<p>(21) International Application Number: PCT/KR96/00040</p> <p>(22) International Filing Date: 25 March 1996 (25.03.96)</p> <p>(30) Priority Data: 1995/6266 24 March 1995 (24.03.95) KR</p> <p>(71) Applicants (for all designated States except US): KOREA GREEN CROSS CORPORATION [KR/KR]; 227, Gugalri, Kiheung-up, Yongin-city, Kyungki-do 449-900 (KR). POSTECH FOUNDATION [KR/KR]; San 31, Hyoja-dong, Nam-ku, Pohang-city, Kyungsangbuk-do 790-784 (KR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): SHIN, Hee, Sup [KR/KR]; 30, Sam-dong, Euwang-city, Kyungki-do 437-040 (KR). SUNG, Young, Chul [KR/KR]; Professor Apartment No. 6-902, Gigok-dong, Pohang-city, Kyungsangbuk-do 790-390 (KR). HONG, Seok, Il [KR/KR]; Mido Apartment No. 102-1306, 511, Daechi-dong, Kangnam-ku, Seoul 135-218 (KR). CHOI, Sun, Sim [KR/KR]; 897, Wangji-dong, Soonchun-city, Chollanam-do 540-330 (KR). YUN, Jin, Won [KR/KR]; 4-28, Guwol-2-dong, Namdong-ku, Inchun 455-202 (KR). CHOI, Eun, Kyoung [KR/KR]; 146, Pyungwha-dong, Kimchun-city, Kyungsangbuk-do 740-090</p>	<p>(KR). PARK, In, Chul [KR/KR]; 1047-48, Sadang-dong, Dongjak-ku, Seoul 156-090 (KR).</p> <p>(74) Agents: YOON, Dong, Yol et al.; Yoon & Lee International Patent & Law Firm, 648-23, Yoksam-dong, Kangnam-ku, Seoul 135-081 (KR).</p> <p>(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>																																																																									
<p>(54) Title: APOPTOSIS REGULATING GENE</p> <p>(57) Abstract</p> <p>A new Bcl-2 related gene "Bfl-1", a polypeptide encoded by said gene, and a plasmid and a transformant comprising said gene are disclosed. The gene can be used to detect cancer.</p>																																																																										
<p style="text-align: center;">Comparison of Bfl-1 and other Bcl-2-related Genes</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">Bcl-2</td> <td style="width: 85%;">MARAGTGYDWTETKNGYIHYKLSDQYVNDQGV 35</td> </tr> <tr> <td>MCL1</td> <td>ATPAELLFPAPTHRAAPLEENAPANDAINSPSELOCTETPLCKRPVPLPLLEVOESQ 153</td> </tr> <tr> <td>Bcl-x</td> <td>NSQSRRLVVTETSLYKLQKQYENQFS 28</td> </tr> <tr> <td>Bak</td> <td>NACGGQPPPPQEGCE 16</td> </tr> </table> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">Bfl-1</td> <td style="width: 85%;">WTICEPOTITRLAQOYLQVLQIPQPSQPSKTERVLQ 38</td> </tr> <tr> <td>A1</td> <td>MAEELNRIIRSLAHTLYVLYQVPFESAPQACRVLQ 38</td> </tr> <tr> <td>Bcl-2</td> <td>GAAPQGAAPAPCIPTSPQNTTKFAASRDPVARTSLQTAAPGAANGPALGVPVPPVHLA 96</td> </tr> <tr> <td>MCL1</td> <td>NMTTDOGLPSTPTFAKESDELYQSLKTSRYLREQDTAKDKPHORSKATSKALET 214</td> </tr> <tr> <td>Bcl-x</td> <td>DNVETNTEALPEOTESDEPTPEALINQPSMILADSFAVIGATCNSSSLOAREYIPIAAVKA 89</td> </tr> <tr> <td>Bak</td> <td>PALPSAESEQAQOTESVPRFVYPRHQDDEBAOVAADPDMVTLPLQPESTNQGVGR 77</td> </tr> <tr> <td>Bax</td> <td>NDGSGQPRDQPTSESDINIKTQALLQGTIQQRASRHOGEAPLALQVFDQASTKL 59</td> </tr> <tr> <td>NR-13</td> <td>MPGLRETTALLLEDITQNRAGGAALPPSATAE 34</td> </tr> </table> <div style="text-align: center; border: 1px solid black; padding: 2px; margin: 10px auto; width: 100px;"> BH1 </div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">Bfl-1</td> <td style="width: 85%;">MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 99</td> </tr> <tr> <td>A1</td> <td>MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 99</td> </tr> <tr> <td>Bcl-2</td> <td>MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 156</td> </tr> <tr> <td>MCL1</td> <td>MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 273</td> </tr> <tr> <td>Bcl-x</td> <td>MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 149</td> </tr> <tr> <td>Bak</td> <td>MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 137</td> </tr> <tr> <td>Bax</td> <td>MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 120</td> </tr> <tr> <td>NR-13</td> <td>MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 95</td> </tr> </table> <div style="text-align: center; border: 1px solid black; padding: 2px; margin: 10px auto; width: 100px;"> BH2 </div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">Bfl-1</td> <td style="width: 85%;">LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 160</td> </tr> <tr> <td>A1</td> <td>LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 160</td> </tr> <tr> <td>Bcl-2</td> <td>LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 215</td> </tr> <tr> <td>MCL1</td> <td>LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 321</td> </tr> <tr> <td>Bcl-x</td> <td>LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 208</td> </tr> <tr> <td>Bak</td> <td>LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 196</td> </tr> <tr> <td>Bax</td> <td>LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 165</td> </tr> <tr> <td>NR-13</td> <td>LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 153</td> </tr> </table> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">Bfl-1</td> <td style="width: 85%;">VTGAIQDRLSLAQYC 175</td> </tr> <tr> <td>A1</td> <td>VTGAIQDRLSLAQYC 172</td> </tr> <tr> <td>Bcl-2</td> <td>VTGAIQDRLSLAQYCITLQAYLSRK 239</td> </tr> <tr> <td>MCL1</td> <td>VTGAIQDRLSLAQYCITLQAYLSRK 350</td> </tr> <tr> <td>Bcl-x</td> <td>VTGAIQDRLSLAQYCITLQAYLSRK 233</td> </tr> <tr> <td>Bak</td> <td>VTGAIQDRLSLAQYCITLQAYLSRK 211</td> </tr> <tr> <td>Bax</td> <td>VTGAIQDRLSLAQYCITLQAYLSRK 193</td> </tr> <tr> <td>NR-13</td> <td>VTGAIQDRLSLAQYCITLQAYLSRK 177</td> </tr> </table>			Bcl-2	MARAGTGYDWTETKNGYIHYKLSDQYVNDQGV 35	MCL1	ATPAELLFPAPTHRAAPLEENAPANDAINSPSELOCTETPLCKRPVPLPLLEVOESQ 153	Bcl-x	NSQSRRLVVTETSLYKLQKQYENQFS 28	Bak	NACGGQPPPPQEGCE 16	Bfl-1	WTICEPOTITRLAQOYLQVLQIPQPSQPSKTERVLQ 38	A1	MAEELNRIIRSLAHTLYVLYQVPFESAPQACRVLQ 38	Bcl-2	GAAPQGAAPAPCIPTSPQNTTKFAASRDPVARTSLQTAAPGAANGPALGVPVPPVHLA 96	MCL1	NMTTDOGLPSTPTFAKESDELYQSLKTSRYLREQDTAKDKPHORSKATSKALET 214	Bcl-x	DNVETNTEALPEOTESDEPTPEALINQPSMILADSFAVIGATCNSSSLOAREYIPIAAVKA 89	Bak	PALPSAESEQAQOTESVPRFVYPRHQDDEBAOVAADPDMVTLPLQPESTNQGVGR 77	Bax	NDGSGQPRDQPTSESDINIKTQALLQGTIQQRASRHOGEAPLALQVFDQASTKL 59	NR-13	MPGLRETTALLLEDITQNRAGGAALPPSATAE 34	Bfl-1	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 99	A1	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 99	Bcl-2	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 156	MCL1	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 273	Bcl-x	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 149	Bak	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 137	Bax	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 120	NR-13	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 95	Bfl-1	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 160	A1	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 160	Bcl-2	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 215	MCL1	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 321	Bcl-x	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 208	Bak	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 196	Bax	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 165	NR-13	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 153	Bfl-1	VTGAIQDRLSLAQYC 175	A1	VTGAIQDRLSLAQYC 172	Bcl-2	VTGAIQDRLSLAQYCITLQAYLSRK 239	MCL1	VTGAIQDRLSLAQYCITLQAYLSRK 350	Bcl-x	VTGAIQDRLSLAQYCITLQAYLSRK 233	Bak	VTGAIQDRLSLAQYCITLQAYLSRK 211	Bax	VTGAIQDRLSLAQYCITLQAYLSRK 193	NR-13	VTGAIQDRLSLAQYCITLQAYLSRK 177
Bcl-2	MARAGTGYDWTETKNGYIHYKLSDQYVNDQGV 35																																																																									
MCL1	ATPAELLFPAPTHRAAPLEENAPANDAINSPSELOCTETPLCKRPVPLPLLEVOESQ 153																																																																									
Bcl-x	NSQSRRLVVTETSLYKLQKQYENQFS 28																																																																									
Bak	NACGGQPPPPQEGCE 16																																																																									
Bfl-1	WTICEPOTITRLAQOYLQVLQIPQPSQPSKTERVLQ 38																																																																									
A1	MAEELNRIIRSLAHTLYVLYQVPFESAPQACRVLQ 38																																																																									
Bcl-2	GAAPQGAAPAPCIPTSPQNTTKFAASRDPVARTSLQTAAPGAANGPALGVPVPPVHLA 96																																																																									
MCL1	NMTTDOGLPSTPTFAKESDELYQSLKTSRYLREQDTAKDKPHORSKATSKALET 214																																																																									
Bcl-x	DNVETNTEALPEOTESDEPTPEALINQPSMILADSFAVIGATCNSSSLOAREYIPIAAVKA 89																																																																									
Bak	PALPSAESEQAQOTESVPRFVYPRHQDDEBAOVAADPDMVTLPLQPESTNQGVGR 77																																																																									
Bax	NDGSGQPRDQPTSESDINIKTQALLQGTIQQRASRHOGEAPLALQVFDQASTKL 59																																																																									
NR-13	MPGLRETTALLLEDITQNRAGGAALPPSATAE 34																																																																									
Bfl-1	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 99																																																																									
A1	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 99																																																																									
Bcl-2	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 156																																																																									
MCL1	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 273																																																																									
Bcl-x	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 149																																																																									
Bak	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 137																																																																									
Bax	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 120																																																																									
NR-13	MAFVQKVEVFNLAELDNVWVVED--NMTTETKPTETSIIMHSLVLELPL 95																																																																									
Bfl-1	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 160																																																																									
A1	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 160																																																																									
Bcl-2	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 215																																																																									
MCL1	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 321																																																																									
Bcl-x	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 208																																																																									
Bak	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 196																																																																									
Bax	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 165																																																																									
NR-13	LKKLLAQQIAPQVDTYKISYFVARE--NMTTETKPTETSIIMHSLVLELPL 153																																																																									
Bfl-1	VTGAIQDRLSLAQYC 175																																																																									
A1	VTGAIQDRLSLAQYC 172																																																																									
Bcl-2	VTGAIQDRLSLAQYCITLQAYLSRK 239																																																																									
MCL1	VTGAIQDRLSLAQYCITLQAYLSRK 350																																																																									
Bcl-x	VTGAIQDRLSLAQYCITLQAYLSRK 233																																																																									
Bak	VTGAIQDRLSLAQYCITLQAYLSRK 211																																																																									
Bax	VTGAIQDRLSLAQYCITLQAYLSRK 193																																																																									
NR-13	VTGAIQDRLSLAQYCITLQAYLSRK 177																																																																									

APOPTOSIS REGULATING GENE

BACKGROUND OF THE INVENTION

5

1. FIELD OF THE INVENTION

The present invention is related to a new apoptosis
regulating gene, a plasmid containing the same, and a
10 peptide encoded by the same.

Several publications are referenced in this
application. Full citation to these references is
found at the end of the specification immediately
preceding the SEQUENCE LISTING or where the publication
15 is mentioned; and each of these publications is hereby
incorporated herein by reference.

2. BACKGROUND OF THE INVENTION

Living cells are programmed to be spontaneously
20 died when they are useless. Such a programmed cell
death is called "Apoptosis" and has widely attracted
attentions in cell physiological fields.

Apoptosis plays an important role in many
physiological processes, such as embryonic development,
25 deletion of self-reactive T-cells (Williams, 1991;
Williams and Smith, 1993), and in many diseases such as
cancer or neurodegenerative disorders. Apoptosis also
plays a critical role in maintaining homeostasis in
many adult tissues. It is widely accepted that cell
30 death and cell proliferation are precisely balanced to
maintain the proper types of cells or tissues, and
disruption of this balance can result in several

carcinogenesis.

Bcl-2 is homologous to the *C. elegans* ced-9 gene, an apoptosis-blocking gene (Hengartner and Horvitz, 1994), and is abundantly expressed in follicular lymphoma that is resulted from the t(14;18) chromosomal translocation (Tsujimoto et al., 1985). It has been known that deaths of a variety of cell types can be prevented by Bcl-2 overexpression, although not all forms of cell death are inhibited (Williams, 1991).

10 Thymocyte overexpressing Bcl-2 were resistant to the induction of apoptosis by glucocorticoid, radiation or anti-CD3 treatments (Sentman et al., 1991; Strasser et al., 1991). Overexpression of Bcl-2 in B cell compartments increases the number of mature resting B

15 cells (Strasser et al., 1991, due to extended cell survival rather than increases proliferation. The action mechanism of the Bcl-2 is not clear yet. Recently, Bcl-2 has been reported to protect apoptosis independent of the inhibition of reactive oxygen

20 species (Jacobson and Raff, 1995; Shimizu et al., 1995), which is contradictory to the previous results (Hockenbery et al., 1993).

Several genes with Bcl-2 related sequences have been reported. Bax, 21 kDa protein, was known to

25 have 21% homology to Bcl-2, and inhibits the function of Bcl-2, perhaps by forming Bcl-2-Bax complex (Oltvai et al., 1993). Bcl-x was reported to have a high-level homology to Bcl-2 and like Bcl-2 prevents apoptotic cell death in IL3-dependent cells following growth

30 factor deprivation (Boise et al., 1993). Bak was

that oncogenesis can be induced by another mechanism, that is, failure of appropriate cell death rather than activation of cellular proliferation.

Under the circumstance that the mechanism of
5 apoptosis at the molecular level is not understood, a finding of a new gene involved in the regulation of apoptosis can accelerate or help an understanding of the mechanism. The new gene can be used to develop a useful diagnostic agent or cancer therapy.

10

SUMMARY OF THE INVENTION

The present invention pertains to a new Bcl-2
15 related genes.

One object of the present invention is to provide Bfl-1 gene, a Bcl-2 related gene from a human fetal liver, comprising bases in SEQ ID NO:1 or equivalents thereof.

20 Other object of the present invention is to provide a plasmid containing the Bfl-1 gene.

Another object of the present invention is to provide a transformant bearing the plasmid.

Still another object of the present invention is
25 to provide a polypeptide comprising amino acids 1 - 175 of SEQ ID NO:2.

BRIEF DESCRIPTION OF THE DRAWINGS

30

cancer tissues. Eight sets of stomach tissues were obtained from eight different stomach cancer patients.

Each set consisted of a normal stomach, tumor tissue and metastatic tumor nodule. Photograph of the
5 corresponding ethidium bromide-stained gel is shown below each autoradiogram. M: metastatic nodule, T:tumor tissue, N: normal stomach tissue.

10 DETAILED DESCRIPTION OF THE INVENTION

The new gene according to the present invention was originally isolated from a human fetal liver at 22 week of gestation and identified by computer analysis of
15 expressed sequenced tag (EST) databases constructed by single-pass sequencing of random cDNA clones (Choi et al., 1995).

A directional cDNA library was constructed from total RNA from a 22 week old human fetal liver, and
20 used for its amplification by using competent cells.

The DNAs were sequenced and each clone was identified. Among the sequenced clones, a clone showing a homology with murine A1 gene was selected and designated as "fl-383d." The fl-383d clone proved to be a new
25 member of the Bcl-2 related gene family, and the new Bcl-2 related gene was named "Bfl-1" ("Bcl-2 related gene expressed in fetal liver").

Bfl-1 gene has a homology with Bcl-2, especially within the BH1 and BH2 domains. Bcl-2 has been shown
30 to prevent apoptotic cell death in cultured cells

by forming heterodimers, Bcl-2-Bax complexes (Oltvai et al., 1993).

Accordingly, the fact that Bfl-1 contains BH1 and BH2 domains strongly suggests that the gene may also be involved in the regulation of apoptosis.

The Bfl-1 gene is highly expressed in bone marrow and present in hemopoietic lineages such as Raji and HL60 and in some normal adult tissues, including lung, spleen, and esophagus. The expression patterns of other Bcl-2 related genes are very distinctive. Bcl-2 is expressed in bone marrow progenitors or long-lived cells in hormonally responsive epithelia that undergo cycles of hyperplasia and in neurons of the peripheral neuronal system (Veis et al., 1993). Bcl-x is highly expressed in the thymus and the central nervous system (Boise et al., 1993). Bax expression was not lymphoid restricted but was widely expressed in a variety of tissues, including lung, stomach, kidney, thymus, bone marrow and spleen (Oltvai et al., 1993). Like Bax, Bak is ubiquitously expressed. Al is a hemopoietic-specific gene expressed in several hemopoietic cell lineages (Lin et al., 1993). It is notable that the expression of apoptosis-accelerating genes such as Bax and Bak is widespread in different tissues, whereas the expression of apoptosis-blocking genes such as Bcl-2, Bcl-x and Al is restricted in some tissues, suggesting that the activity of apoptosis-accelerating genes may be regulated by death inhibitory genes.

Interestingly, the expression of Bfl-1 appears to

al., 1994).

The present invention also provides equivalent DNA constructs that encode various additions or substitutions of amino acid residues or sequences, or
5 deletions of terminal or internal residues or sequences not needed for biological activity of the polypeptide comprising the amino acids 1 - 175 of SEQ ID NO:2.

Nucleic acid sequences within the scope of the invention include isolated DNA and RNA sequences that
10 hybridize to the cDNA nucleotide sequences disclosed herein under conditions of moderate or severe stringency, which encode the polypeptide comprising the amino acids 1 - 175 of SEQ ID NO:2. Conditions of moderate stringency, as defined by Sambrook et al.,
15 Molecular Cloning : A Laboratory Manual, 2nd ed, Vol. 1, pp.1.101-104, Cold Spring Harbor Laboratory Press, (1989), include use of a prewashing solution of 5 X SSC, 1.0 mM EDTA (pH 8.0) and hybridization conditions of about 55°C, 5 X SSC, overnight. Conditions of
20 severe stringency include higher temperatures of hybridization and washing. The skilled artisan will recognize that the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as the length of the probe.

25 Due to the known degeneracy of the genetic code wherein more than one codon can encode the same amino acid, a DNA sequence may vary from that shown in SEQ ID NO:1 and still encode the polypeptide having the amino acid sequence of SEQ ID NO:2.

reaction, samples were run in a 4.5% polyacrylamide gel. The gel was soaked in a solution consisting of 10% of methanol and 10% of acetic acid for 15 to 30 min, dried, and exposed to an X-ray film at room temperature for 12 to 14 hours.

Comparison between the generated sequences and public databases (Genbank, SWISS-PORT and PIR) was performed using BLAST program. The multiple sequence alignment was performed using the software package IG suite (IntelliGenetics Co, Mountain View, CA), installed on a SUN SPARC Station 2 computer (SUN Microsystems, Inc, Mountain View, CA).

3. Northern analysis

Total RNA of tissues and cell lines was isolated using guanidine thiocyanate protocol (Sambrook et al., 1989). About 20-30 µg of total RNA was loaded per lane of 1% denaturing formaldehyde agarose gel and run at 40V for 16 hours. The RNA was transferred to a nylon membrane (Schleicher and Schuell) using 10 X SSC.

Radioactivity labeled probes (2×10^5 c.p.m. per ml) were hybridized to the blots at 65°C in a buffer as described by Church and Gilbert (1984). After 18 h hybridization, the filters were washed in a buffer containing 0.1 X SSC, 0.1% SDS at 65°C for 15 min. The autoradiogram was taken for 1-7 days (Kang et al., 1994).

Results

1. Identification of a novel gene related to Bcl-2

"-4" is given when the amino acids compared are the different from each other. Therefore, the higher the score, the more homologous the amino acid sequences. The "p-value" also is a computerized value and 5 indicates the possibility of an accidental match. Accordingly, the lower the value, the more specific the match.

The results of amino acid homology evaluation reveals that the Bfl-1 products shows the highest 10 homology with the polypeptide L16462, an A1 gene product.

The detailed comparison of amino acids of the Bfl-1 and A1 products are shown in FIG. 2. As can be seen from FIG. 2, Bfl-1 gene shows similarity throughout the 15 partially sequenced bases from its first amino acid, Met. The size of cDNA insert is about 750bp, which is similar to that of A1 transcript.

The new Bcl-2 related gene according to the present invention is now named "Bfl-1 (Bcl-2 related gene 20 expressed in fetal liver)."

The A1 gene is a Bcl-2 related gene in the mouse and is known as a hemopoietic specific deary response gene whose transcription is rapidly and transiently induced by GM-CSF in murine bone marrow-derived 25 macrophage (Lin et al., 1993). Since the Bcl-2 related genes play an important role in the regulation of apoptosis, the present inventors have determined the full DNA sequence of the novel cDNA gene and deduced the amino acid sequence of a potential open reading 30 frame (SEQ ID NO:1). Bfl-1 is consisted of 734 bp and

the BH1 and BH2 domains, which have been known to be important for Bcl-2 function, indicating that the human cDNA clone fl-383d represents a new member of the Bcl-2 related gene family.

5

2. The Bfl-1 gene is abundantly expressed in bone marrow and at a low level in some other tissues

To examine the expression pattern of Bfl-1, northern blot analysis was performed on various human
10 tissues and cell lines (FIG. 5). Because Bfl-1 was initially identified from a human fetal liver at 22 weeks of gestation, which consists of hepatic and hemopoietic cells, the present inventors performed northern analysis of fetal liver, hemopoietic lineage
15 cells such as HL60 and Raji, and primary acute lymphocyte leukemia (ALL) cells. The results are shown in FIG. 4. Bfl-1 was highly expressed in bone marrow, but not detected in fetal liver, indicating that the level of Bfl-1 expression is not high in the
20 fetal liver (FIG. 4A). The Raji cell line derived from Burkitt's lymphoma expressed Bfl-1, whereas the other cell lines did not express Bfl-1, or did very little, if any. On northern analysis with various normal adult tissues, Bfl-1 message was detected at low
25 levels in lung, spleen, and esophagus (FIG. 4B). No Bfl-1 message was detected in several other nonhemopoietic tissues including heart, testis, thyroid, cerebellum and cerebrum.

30 3. *The expression of Bfl-1 is activated in stomach*

REFERENCES

1. Bissonnette RP, Echeverri F, Mahboubi A and Green GR. (1992), *Nature*, 359, 552-554
2. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L,
5 Lindstein T, Turka LA, Mao X, Nunez G and Thompson CB. (1993), *Cell*, 74, 597-608
3. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M and Nunez G. (1993), *Am. J. Pathol.*, 143, 1543-1550.
- 10 4. Choi SS, Yun JW, Choi EK, Cho YG, Sung YC and Shin HS. (1995), *Mammalian Genome* (in press).
5. Chittenden GI and Gullid BC. (1995), *Nature*, 374, 733-736
6. Church G and Gilbert W. (1984), *Proc. Natl. Aca. Sci. USA*, 81, 1991-1995.
- 15 7. Clark AR, Purdie CA, Herrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH. (1993), *Nature*, 362, 849-852
8. Duke RC and Cohen JJ. (1986), *Lymphokine Res.*, 5, 289-299
- 20 9. Fanidi A, Harrington EA and Evan G. (1992), *Nature*, 359, 554-556.
10. Farrow SN, White JHM, Martinou I, Raven T, Pun K-T, Grinham CJ, Martinous J-C and Brown R. (1995),
25 *Nature*, 374, 731-733.
11. Fisher DE. (1994), *Cell*, 79, 539-542.
12. Garcia I, Hengartner MO and Horvitz HR. (1994), *Cell*, 76, 665-676.
13. Garcia I, Martina I, Tsujimoto Y and Martiou J-C.
30 (1992), *Science*, 258, 302-304.

28. Morgenbesser SD, Williams BO, Jacks T and Depinho RA. (1994), *Nature*, 371, 72-74.
29. Nunez G and Clarke MF. (1994), *Trends in Cell Biol.*, 4, 399-403.
- 5 30. Nunez G, London L, Hockenbery D, Alexander M, Mckearn JP and Korsmeyer SJ. (1990), *Immunol.*, 144, 3602-3610.
31. Nunez G, Merino R, Grillot D and Gonzalez-Garcia M. (1994), *Immunol. Today*, 15, 582-587.
- 10 32. Oltvai ZN, Millman CL and Korsmeyer SJ. (1993), *Cell*, 74, 609-619.
33. Osborne BA and Schwartz LM. (1994), *Trends in Cell Biol.*, 4, 394-399.
34. Papadopoulos N, Nicolaides NC, Wei Y-F, Ruben SM, 15 Carter KC, Rosen CA, Haseltaine WA, Fleischmann RD, Fraser CM, Adams MD, Venter JC, Hamilton SR, Peterson GM, Watson P, Lynch HT, Peltomaki P, Mecklin JP, Chapelle A, Kinzler KW and Vogelstein B. (1994), *Science*, 263, 1625-1628.
- 20 35. Reed JC, Cuddy M, Slabick T, Croce CM and Nowell PC. (1988), *Nature*, 336, 259-261.
36. Sambrook J, Fritsch EF and Maniatis T. (1989), *Molecular Cloning*, 1, n.3-n.36.
37. Sentman CL, Shutter JR, Hockenbery D, Kanakawa O 25 and Korsmeyer SJ. (1991), *Cell*, 67, 879-888.
38. Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H and Tsujimoto Y. (1995), *Nature*, 374, 811-813.
39. Strasser A, Harris AW and Cory S. (1991). *Cell*, 67, 889-899.
- 30 40. Strasser A, Harris AW, Bath ML and Cory S. (1990).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- 5 (i) APPLICANT:
(A) NAME: Korea Green Cross Corporation
(B) STREET: 227 Gugal-ri, Kiheung-up
(C) CITY: Yongin
(D) STATE: Kyongki
10 (E) COUNTRY: Republic of Korea
(F) POSTAL CODE (ZIP): 449-900

(A) NAME: Postech Foundation
(B) STREET: San 31, Hyoja-dong, Nam-ku
15 (C) CITY: Pohang
(D) STATE: Kyoungbuk
(E) COUNTRY: Republic of Korea
(F) POSTAL CODE (ZIP): 790-330
- 20 (ii) TITLE OF INVENTION: Apoptosis Regulating Gene
(iii) NUMBER OF SEQUENCES: 2
(iv) COMPUTER READABLE FORM:
25 (A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0,
Version #1.30 (EPO)
30 (v) CURRENT APPLICATION DATA:
APPLICATION NUMBER: To be assigned
(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: KR 1995-6266
35 (B) FILING DATE: 24-MAR-1995

(2) INFORMATION FOR SEQ ID NO: 1:

- 40 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 755 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
45 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
50 (iv) ANTI-SENSE: NO
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(D) DEVELOPMENTAL STAGE: Fetus
55 (F) TISSUE TYPE: Liver

25

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 175 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Thr Asp Cys Glu Phe Gly Tyr Ile Tyr Arg Leu Ala Gln Asp Tyr
 1 5 10 15

15 Leu Gln Cys Val Leu Gln Ile Pro Gln Pro Gly Ser Gly Pro Ser Lys
 20 25 30

20 Thr Ser Arg Val Leu Gln Asn Val Ala Phe Ser Val Gln Lys Glu Val
 35 40 45

25 Glu Lys Asn Leu Lys Ser Cys Leu Asp Asn Val Asn Val Val Ser Val
 50 55 60

30 Asp Thr Ala Arg Thr Leu Phe Asn Gln Val Met Glu Lys Glu Phe Glu
 65 70 75 80

35 Asp Gly Ile Ile Asn Trp Gly Arg Ile Val Thr Ile Phe Ala Phe Glu
 85 90 95

Gly Ile Leu Ile Lys Lys Leu Leu Arg Gln Gln Ile Ala Pro Asp Val
 100 105 110

40 Asp Thr Tyr Lys Glu Ile Ser Tyr Phe Val Ala Glu Phe Ile Met Asn
 115 120 125

45 Asn Thr Gly Glu Trp Ile Arg Gln Asn Gly Gly Trp Glu Asn Gly Phe
 130 135 140

Val Lys Lys Phe Glu Pro Lys Ser Gly Trp Met Thr Phe Leu Glu Val
 50 145 150 155 160

Thr Gly Lys Ile Cys Glu Met Leu Ser Leu Leu Lys Gln Tyr Cys
 165 170 175

55

9, wherein said cancer is stomach cancer.

2/5
FIG. 2

Bf1-1 NTDCFEFGYIYRLAQDYLCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVEKNLKSCLDNVNV 61
M + E +I+ LA+ YLQ VLQ+P S PS+ RVLQ VAFSVQKEVEKNLKS LD+ +V
A1 MAESELMIHIIISLAEHYLYVLQVPAFESAPSQACRVLQRVAFSVQKEVEKNLKS YLDDFHV 61

Bf1-1 VSVDTARTLFNQVMEKEFEDGIINWGRIVTIFAFEGILIEKLLRQIAPDVDYKEISYFV 118
S+DTAR +FNQVMEKEFEDGIINWGRIVTIFAF G L+KKL ++QIA DV YK++S FV
A1 ESIDTARIIFNQVMEKEFEDGIINWGRIVTIFAFGGVLLKKLPQEIALDVCAYKQVSSFV 122

Bf1-1 AEFIMNNTGEWIRQNGGWENGFKKFEPKSGWMTFLEVTGKICEMLSLLKQYC 175
AEFIMNNTGEWIRQNGGWE+GF+KKFEPKSGW+TFL++TG+I EML LLK
A1 AEFIMNNTGEWIRQNGGWEDGFIKKFEPKSGWLTFLQMTGQIWENLFLLK 172

4/5


FIG. 4

Northern blot analysis of Bfl-1 gene expression in several
human tissues and cell lines

A


fetal liver
adult liver
hepatic tumor
nontumor
bone-marrow
HL60
H9
Raji
ALL

18S-



B

kidney
lung
spleen
esophagus
heart
testis
thyroid
cerebellum
cerebrum



INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00040

A. CLASSIFICATION OF SUBJECT MATTER

IPC⁶: C 12 N 15/12; C 12 Q 1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁶: C 12 N 15/12; C 12 Q 1/68

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93/20 200 A1 (IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED) 14 October 1993 (14.10.93), claim 26; pages 75-78.	1-10
A	THE JOURNAL OF IMMUNOLOGY, Vol.151, No.4, 15 August 1993 (15.08.93), Baltimore, USA E.Y.LIN et al.: "Characterization of A1, a Novel Hemopoietic - Specific Early - Response Gene with Sequence Similarity to bcl-2", pages 1979-1988; page 1981, fig.1.	1-10
A	The EMBO Journal, Vol.14, No.5, 01 March 1995 (01.03.95), Oxford (GB), G. GILLET et al.: "A BCL-2-related gene is activated in avian cells transformed by the Rous sarcoma virus", pages 1372-1381; page 1376.	1-10
A	CELL, Vol.76, No.4, 25 February 1994 (25.02.94), Cambridge (Mass., USA), M.O. HENGARTNER et al.: C.elegans Cell Survival Gene ced-9 Encodes a Functional Homolog of the Mammalian Proto-Oncogene bcl-2", pages 665-676; page 670, fig.7.	1-10

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

12 June 1996 (12.06.96)

Date of mailing of the international search report

19 June 1996 (19.06.96)

Name and mailing address of the ISA/ AT
AUSTRIAN PATENT OFFICE
Kohlmarkt 8-10
A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Wolf

Telephone No. 1/53424/133